• Liraglutide revenue outlook: Following approvals across the US, the UK, and Europe, Biocon expects generic Liraglutide sales to reach up to $100 million, supported by vertical integration and limited market competition.
• Indian GLP-1 strategy: Biocon is deprioritizing immediate Phase 3 clinical trials in India due to severe margin pressure from expected domestic price wars (with treatments dropping to ₹5,000 monthly), choosing instead to focus on export markets.
• Long-term GLP-1 target: Driven by Semaglutide patent expiries in the US and Europe by 2031 alongside earlier opportunities in Canada and emerging markets, the GLP-1 portfolio is projected to generate a couple of hundred million dollars for the company.
• Freight and margin impact: Geopolitical disruptions around the Strait of Hormuz have forced Biocon to airlift exports at approximately three times the cost of sea freight, though the overall earnings margin impact is expected to remain under one percent.